Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Makamson

Vascular Surgery Mobile, AL Doctor of Osteopathy

NPI 1518960038 CMS profile 159692

1151 Dauphin St, Mobile, AL 36604

Open in the dashboard

General payments

$17,606

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Makamson of Mobile, AL is reported in the CMS Open Payments database as having received $17,606 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $571 17
2024 General $2,735 17
2023 General $613 14
2022 General $4,713 42
2021 General $1,902 40
2020 General $578 18
2019 General $6,494 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Makamson
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Benjamin Makamson were reported at $571. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Benjamin Makamson Vascular Surgery median Middle half National median
2019 $6,494 $796 $226–$2,363 $163
2020 $578 $348 $118–$1,110 $114
2021 $1,902 $471 $158–$1,421 $132
2022 $4,713 $725 $222–$2,183 $149
2023 $613 $836 $257–$2,440 $160
2024 $2,735 $909 $252–$2,619 $164
2025 $571 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cardiovascular Systems Inc. $4,166 38 payments
  2. Siemens Medical Solutions USA, Inc. $4,111 6 payments
  3. Globus Medical, Inc. $2,403 4 payments
  4. Organogenesis Inc. $1,814 8 payments
  5. Penumbra, Inc. $1,259 22 payments
  6. Medtronic, Inc. $603 14 payments
  7. Philips Electronics North America Corporation $416 6 payments
  8. Bard Peripheral Vascular, Inc. $368 7 payments
  9. Terumo Medical Corporation $361 4 payments
  10. Janssen Pharmaceuticals, Inc $239 17 payments
  11. Other $1,866 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,981 184 payments
  2. Travel and Lodging $3,225 8 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,400 1 payment
  4. Consulting Fee $2,000 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
Products named General payments · program years 2019–2025
  1. Peripheral Orbital Atherectomy System $3,590 15 payments
  2. Corbel $2,403 4 payments
  3. Puraply $1,661 5 payments
  4. Indigo System $1,146 21 payments
  5. Diamondback Peripheral $545 22 payments
  6. ENDURANT IIS $464 6 payments
  7. XARELTO $239 17 payments
  8. CLOTTRIEVER BOLD CATHETER $189 3 payments
  9. (9281) Turbo Elite $169 2 payments
  10. BioMimics 3D Vascular Stent System $144 2 payments
  11. Other $2,969 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

242

Median for Vascular Surgery: 122

Drug cost

$44,791

Median for Vascular Surgery: $14,135

Branded share of claims

87.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 43 $36,486
Eliquis Apixaban Brand 11 $6,435
Clopidogrel Clopidogrel Bisulfate Brand 140 $1,562
Doxycycline Hyclate Generic 16 $138
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $116
Atorvastatin Calcium Generic 15 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$454,583

Medicare's payments for the services billed

Medicare patients

230

Average age 76

Services billed

1,194

115 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 59%
Chronic kidney disease 53%
Diabetes 50%
Heart failure 47%
Atrial fibrillation 41%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record